$HALB News April 04, 2024 Halberd's Patented Drug, LDN+, the Subject of a Limited Clinical Trial Under an Innovative Four-Company Cooperative Research and Development (CRADA) Contract https://finance.yahoo.com/news/halberds-patented-drug-ldn-subject-132000576.html